DJIA 16,658.74 197.42 1.20%
NASDAQ 4,427.61 44.76 1.02%
S&P 500 1,944.59 17.48 0.91%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)



company name or ticker

Advertising And The Belviq Re-Launch

Biotech Investing: 3 Ways You're Doing It Wrong

Biotech investing might appear easy considering some of the big gains we've witnessed in recent years, but these three common mistakes make it very difficult for the average biotech investor to make money.

Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind

Arena And VIVUS: A Case Study In Small-Cap Pharma

Belviq Sales Flatten Out But Edge Above Qsymia

FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another

The 52-Week Low Club for Wednesday

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog

VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog

Arena's Belviq Bucks Seasonality With 3.6% Week Over Week Gain

See More Articles...